These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 37258054)

  • 21. Risk Factors of Coronary Artery Abnormalities and Resistance to Intravenous Immunoglobulin Plus Corticosteroid Therapy in Severe Kawasaki Disease: An Analysis of Post RAISE.
    Miyata K; Miura M; Kaneko T; Morikawa Y; Sakakibara H; Matsushima T; Misawa M; Takahashi T; Nakazawa M; Tsuchihashi T; Yamashita Y; Obonai T; Chiga M; Hori N; Komiyama O; Yamagishi H
    Circ Cardiovasc Qual Outcomes; 2021 Feb; 14(2):e007191. PubMed ID: 33541111
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A registry study of Kawasaki disease patients with coronary artery aneurysms (KIDCAR): a report on a multicenter prospective registry study three years after commencement.
    Koyama Y; Miura M; Kobayashi T; Hokosaki T; Suganuma E; Numano F; Furuno K; Shiono J; Ebata R; Fuse S; Fukazawa R; Mitani Y
    Eur J Pediatr; 2023 Feb; 182(2):633-640. PubMed ID: 36434403
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anakinra Treatment in Patients with Acute Kawasaki Disease with Coronary Artery Aneurysms: A Phase I/IIa Trial.
    Yang J; Jain S; Capparelli EV; Best BM; Son MB; Baker A; Newburger JW; Franco A; Printz BF; He F; Shimizu C; Hoshino S; Bainto E; Moreno E; Pancheri J; Burns JC; Tremoulet AH
    J Pediatr; 2022 Apr; 243():173-180.e8. PubMed ID: 34953816
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravenous immunoglobulin for the treatment of Kawasaki disease.
    Broderick C; Kobayashi S; Suto M; Ito S; Kobayashi T
    Cochrane Database Syst Rev; 2023 Jan; 1(1):CD014884. PubMed ID: 36695415
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The time option of IVIG treatment is associated with therapeutic responsiveness and coronary artery abnormalities but not with clinical classification in the acute episode of Kawasaki disease.
    Samadli S; Liu FF; Mammadov G; Wang JJ; Liu HH; Wu YF; Luo HH; Wu Y; Chen WX; Zhang DD; Wei W; Hu P
    Pediatr Rheumatol Online J; 2019 Jul; 17(1):53. PubMed ID: 31366406
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Giant aneurysms: A gender-specific complication of Kawasaki disease?
    Dietz SM; Kuipers IM; Tacke CEA; Koole JCD; Hutten BA; Kuijpers TW
    J Cardiol; 2017 Oct; 70(4):359-365. PubMed ID: 28325522
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeted Use of Prednisolone with Intravenous Immunoglobulin for Kawasaki Disease.
    Sakai H; Iwashima S; Sano S; Akiyama N; Nagata E; Harazaki M; Fukuoka T
    Clin Drug Investig; 2021 Jan; 41(1):77-88. PubMed ID: 33341911
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Non-coronary cardiac events, younger age, and IVIG unresponsiveness increase the risk for coronary aneurysms in Italian children with Kawasaki disease.
    Fabi M; Andreozzi L; Frabboni I; Dormi A; Corinaldesi E; Lami F; Cicero C; Tchana B; Francavilla R; Sprocati M; Bigucci B; Balsamo C; Valin PS; Di Fazzio G; Iughetti L; Valletta E; Marchetti F; Donti A; Lanari M
    Clin Rheumatol; 2021 Apr; 40(4):1507-1514. PubMed ID: 32936425
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic nutrition index as a predictor of coronary artery aneurysm in Kawasaki Disease.
    Tai IH; Wu PL; Guo MM; Lee J; Chu CH; Hsieh KS; Kuo HC
    BMC Pediatr; 2020 May; 20(1):203. PubMed ID: 32393306
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive factors of medium-giant coronary artery aneurysms in Kawasaki disease.
    Jiang S; Li M; Xu K; Xie Y; Liang P; Liu C; Su Q; Li B
    Pediatr Res; 2024 Jan; 95(1):267-274. PubMed ID: 37670043
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of different doses of aspirin on the prognosis of Kawasaki disease.
    Wang J; Chen H; Shi H; Zhang X; Shao Y; Hang B; Xu Z; Rong X; Chu M; Qiu H
    Pediatr Rheumatol Online J; 2020 Jun; 18(1):48. PubMed ID: 32527316
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Coronary artery aneurysm regression after Kawasaki disease and associated risk factors: a 3-year follow-up study in East China.
    Tang Y; Yan W; Sun L; Xu Q; Ding Y; Lv H
    Clin Rheumatol; 2018 Jul; 37(7):1945-1951. PubMed ID: 29330741
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A practical nomogram for predicting coronary thrombosis for Kawasaki disease patients with medium or large coronary artery aneurysm.
    Peng Y; Cheng Z; Yi Q
    Clin Exp Med; 2023 Aug; 23(4):1317-1324. PubMed ID: 36151486
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacologic interventions for Kawasaki disease in children: A network meta-analysis of 56 randomized controlled trials.
    Lei WT; Chang LS; Zeng BY; Tu YK; Uehara R; Matsuoka YJ; Su KP; Lee PC; Cavalcante JL; Stubbs B; Lin PY; Wu YC; Hsu CW; Chen TY; Chen YW; Yeh PY; Sun CK; Tseng PT; Kao YH
    EBioMedicine; 2022 Apr; 78():103946. PubMed ID: 35306339
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interleukin-6 is prone to be a candidate biomarker for predicting incomplete and IVIG nonresponsive Kawasaki disease rather than coronary artery aneurysm.
    Wu Y; Liu FF; Xu Y; Wang JJ; Samadli S; Wu YF; Liu HH; Chen WX; Luo HH; Zhang DD; Wei W; Hu P
    Clin Exp Med; 2019 May; 19(2):173-181. PubMed ID: 30617865
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predicting IVIG resistance in UK Kawasaki disease.
    Davies S; Sutton N; Blackstock S; Gormley S; Hoggart CJ; Levin M; Herberg JA
    Arch Dis Child; 2015 Apr; 100(4):366-8. PubMed ID: 25670405
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Japanese Kawasaki Disease Scoring Systems: Are they Applicable to the Iranian Population?
    Edraki MR; Mohammadi H; Mehdizadegan N; Ghorashi M; Amoozgar H; Borzouee M; Ajami G; Keshavarz K; Dehghani E; Bahrami R
    Arch Iran Med; 2020 Jan; 23(1):31-36. PubMed ID: 31910632
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Higher efficacy of infliximab than immunoglobulin on Kawasaki disease, a meta-analysis.
    Li X; Tang Y; Ding Y; Chen Y; Hou M; Sun L; Qian G; Qin L; Lv H
    Eur J Pharmacol; 2021 May; 899():173985. PubMed ID: 33652059
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Kawasaki Disease Comparative Effectiveness (KIDCARE) trial: A phase III, randomized trial of second intravenous immunoglobulin versus infliximab for resistant Kawasaki disease.
    Roberts SC; Jain S; Tremoulet AH; Kim KK; Burns JC; ; Anand V; Anderson M; Ang J; Ansusinha E; Arditi M; Ashouri N; Bartlett A; Chatterjee A; DeBiasi R; Dekker C; DeZure C; Didion L; Dominguez S; El Feghaly R; Erdem G; Halasa N; Harahsheh A; Jackson MA; Jaggi P; Jain S; Jone PN; Kaushik N; Kurio G; Lillian A; Lloyd D; Manaloor J; McNelis A; Michalik DE; Newburger J; Newcomer C; Perkins T; Portman M; Romero J; Ronis T; Rowley A; Schneider K; Schuster J; Tejtel SKS; Sharma K; Simonsen K; Szmuszkovicz J; Truong D; Wood J; Yeh S
    Contemp Clin Trials; 2019 Apr; 79():98-103. PubMed ID: 30840903
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Z-score is a possible predictor of the risk of coronary artery lesion development in patients with Kawasaki disease in Japan.
    Suzuki T; Kakimoto N; Tsuchihashi T; Suenaga T; Takeuchi T; Shibuta S; Kitano N; Suzuki H
    Eur J Pediatr; 2021 Sep; 180(9):2797-2805. PubMed ID: 33763715
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.